Oral Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2017

Assessing the benefits of anticancer drugs: update on the ASCO and ESMO value framework (#18)

Nicola Lawrence 1
  1. NHMRC CTC, Camperdown, NSW, Australia

Worldwide the costs of health care are increasing rapidly, and this is particularly true for expenditure on new anticancer drugs. It is important to assess the value of new anticancer drugs, weighing up the balance between benefits, harms and costs.

The world’s two leading medical oncology organisations, the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), have formulated objective, validated and reproducible frameworks to assess the value of anticancer drugs.1,2 These frameworks aim to improve transparency and provide independent measures of the degree of benefit a treatment offers. Both frameworks use data from individual clinical trials to assess the value of a new treatment in comparison with the standard of care used in the trial.

Important similarities and differences will be highlighted, as well as potential applications to health policy and clinical applications.

  1. Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, et al. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(24):2925-34.
  2. Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2015;26(8):1547-73.